Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Steen

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|March 31, 2022
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical TrialDinesh Khanna, Paul Caldron, Richard W Martin, et al.
Journal of Scleroderma and Related Disorders|July 28, 2021
Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomesAlain Lescoat, Susan L Murphy, David Roofeh, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Annals of the Rheumatic Diseases|February 7, 2012
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registrySangmee Bae, Rajeev Saggar, Marcy B Bolster, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis and Rheumatism|February 28, 2009
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialLorinda Chung, Lee Shapiro, David Fiorentino, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyLisa R Jewett, Linda Kwakkenbos, Marie-Eve Carrier, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group ReportElizabeth R Volkmann, Jill Siegfried, Tim Lahm, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Arthritis & Rheumatology (Hoboken, N.J.)|March 31, 2022
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical TrialDinesh Khanna, Paul Caldron, Richard W Martin, et al.
Journal of Scleroderma and Related Disorders|July 28, 2021
Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomesAlain Lescoat, Susan L Murphy, David Roofeh, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Annals of the Rheumatic Diseases|February 7, 2012
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registrySangmee Bae, Rajeev Saggar, Marcy B Bolster, et al.
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis and Rheumatism|February 28, 2009
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialLorinda Chung, Lee Shapiro, David Fiorentino, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyLisa R Jewett, Linda Kwakkenbos, Marie-Eve Carrier, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group ReportElizabeth R Volkmann, Jill Siegfried, Tim Lahm, et al.
Pageof 9